GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Satellos Bioscience Inc (TSX:MSCL) » Definitions » Stock Based Compensation

Satellos Bioscience (TSX:MSCL) Stock Based Compensation : C$2.70 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Satellos Bioscience Stock Based Compensation?

Satellos Bioscience's Stock Based Compensation for the three months ended in Mar. 2024 was C$0.74 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2024 was C$2.70 Mil.


Satellos Bioscience Stock Based Compensation Historical Data

The historical data trend for Satellos Bioscience's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Satellos Bioscience Stock Based Compensation Chart

Satellos Bioscience Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Stock Based Compensation
0.09 0.97 1.44 2.17

Satellos Bioscience Quarterly Data
Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.20 0.37 0.74 0.85 0.74

Satellos Bioscience Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$2.70 Mil.


Satellos Bioscience Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Satellos Bioscience's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


Satellos Bioscience (TSX:MSCL) Business Description

Traded in Other Exchanges
Address
65 Front Street East, Suite 201, Toronto, ON, CAN, M5E 1B5
Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.

Satellos Bioscience (TSX:MSCL) Headlines

No Headlines